JP2005336208A - Composition for extending post meal satiety - Google Patents

Composition for extending post meal satiety Download PDF

Info

Publication number
JP2005336208A
JP2005336208A JP2005235268A JP2005235268A JP2005336208A JP 2005336208 A JP2005336208 A JP 2005336208A JP 2005235268 A JP2005235268 A JP 2005235268A JP 2005235268 A JP2005235268 A JP 2005235268A JP 2005336208 A JP2005336208 A JP 2005336208A
Authority
JP
Japan
Prior art keywords
nutritional composition
composition
satiety
weight
nutritional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005235268A
Other languages
Japanese (ja)
Inventor
Robert Portman
ポートマン，ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemin Consumer Care LC
Original Assignee
Kemin Consumer Care LC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemin Consumer Care LC filed Critical Kemin Consumer Care LC
Publication of JP2005336208A publication Critical patent/JP2005336208A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pediatric Medicine (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a nutritional composition which extends post meal satiety. <P>SOLUTION: The nutritional composition in a dry powder form includes an extract of potatoes which provides a proteinase inhibitor source and is mixed with water and digested before a meal, extends satiety, and thereby reduces appetite. This nutritional composition includes about 10 to about 80 wt.% protein, about 10 to about 40 wt.% medium to long chain fatty acid, about 2 to about 5 wt.% calcium salt, and about 1 to about 5 wt.% proteinase inhibitor provided by the extract of potatoes. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

発明の詳細な説明Detailed Description of the Invention

発明の背景Background of the Invention

発明の分野
本発明は、食事のあとの飽満を延ばすための栄養組成物に関する。さらに詳しくは、その組成物は、蛋白質、中鎖及び／または長鎖脂肪酸及びコレシストキニン胃腸ペプチドの分泌を刺激するためのカルシウム、及びコレシストキニンの分解を防止するジャガイモから抽出されたプロテイナーゼ阻害剤の源、を包含する。コレシストキニンの水準を増加し、維持することによって、本考案は飽満を引き延ばす。 The present invention relates to a nutritional composition for prolonging satiety after a meal. More specifically, the composition comprises protein, medium and / or long chain fatty acids and calcium to stimulate secretion of cholecystokinin gastrointestinal peptide, and proteinase inhibition extracted from potato that prevents cholecystokinin degradation. The source of the agent. By increasing and maintaining the level of cholecystokinin, the present invention prolongs satiety.

先行技術の背景
過去４０年にわたって、食事の摂取後の飽満を引き延ばすであろう機構について広範囲な研究が行われてきている。そのような考案の恩恵は、体重の減量を行う明らかな利用性を有する。体重減量研究は、三つの分野に焦点を置いている。脳は食欲の制御において主要な役割を果たすので、研究者達は種々の神経伝達物質、特にセロトニン（ｓｅｒｏｔｏｎｉｎｅ）、ドーパミン（ｄｏｐａｍｉｎｅ）及びノル−エピネフリン（ｎｏｒ−ｅｐｉｎｅｐｈｒｉｎｅ）を調べてきている。これらの神経伝達物質に影響を与える多数の処方薬及び一般薬製品が開発され、食欲を低減させている。薬理学的に食欲を低減させることは、ある時間の終りまでに効果が失われること、を包含する多数の欠点を有する。神経伝達物質に影響を与える薬剤は、中枢神経系統にも影響を与え、神経過敏及び不安を引起こしうる。さらには、これらの薬剤は、致命的であり得る心臓血管への影響を生じ得る。 Background of the Prior Art Over the past 40 years, extensive research has been conducted on mechanisms that may prolong satiety after eating a meal. The benefit of such a device has a clear utility for weight loss. Weight loss studies focus on three areas. Since the brain plays a major role in the control of appetite, researchers have been investigating various neurotransmitters, particularly serotonin, dopamine, and nor-epinephrine. A number of prescription and general drug products that affect these neurotransmitters have been developed to reduce appetite. Pharmacologically reducing appetite has a number of drawbacks, including loss of effectiveness by the end of a certain time. Agents that affect neurotransmitters can also affect the central nervous system, causing irritability and anxiety. Furthermore, these agents can produce cardiovascular effects that can be fatal.

第２のアプローチは、胃腸が空になるのを遅延させ、それによって満腹感を生じさせることに焦点が置かれてきている。このアプローチは、不溶性繊維を利用し、繊維が胃腸管内の食物の移動を遅くする。繊維の使用に伴う欠点は、一定の効果を生じさせるのに必要とされる量が、口当たりの良くない食物、ならびに鼓脹、ガス及び下痢を含む多くの胃腸への影響、を生じさせる。   The second approach has been focused on delaying gastrointestinal emptying, thereby creating a feeling of fullness. This approach utilizes insoluble fiber, which slows the movement of food in the gastrointestinal tract. The disadvantages associated with the use of fiber cause the amount of food needed to produce a certain effect, as well as bad food and many gastrointestinal effects including bloating, gas and diarrhea.

第３のアプローチは、身体の飽満機構を刺激することを研究する。食物が消費されるときに、コレシストキニン放出蛋白質[Ｃｈｏｌｅｃｙｓｔｏｋｉｎｉｎ
Ｒｅｌｅａｓｉｎｇ Ｐｒｏｔｅｉｎ（ＣＣＫ−ＲＰ）]と称されるペプチドが放出される。次いでコレシストキニン放出蛋白質が腸におけるコレシストキニンの放出を刺激する。コレシストキニンは飽満を増大することが示されている。コレシストキニンが放出されるときに、それは、ＣＣＫ−ＲＰを不活性化させる酵素の放出も刺激する。ＣＣＫ−ＲＰが不活性化されるときに、ＣＣＫ水準が降下し、飽満感は減少される。研究によって、コレシストキニンは食事摂取後の飽満を引き延ばすのに極めて効果的であることが示されてきている。ＣＣＫは飽満を延ばし、食物の採込みを低減させることが示されたが、主要な欠点は、それが静脈注射で与えられなければならないことである。経口投与されるときには、ＣＣＫは胃腸酵素によって不活性化される。このことは、可能性のある体重減量剤としてのその利用を著しく制限してきた。 The third approach studies stimulating the body's satiety mechanism. When food is consumed, cholecystokinin releasing protein [Cholecystokinin
A peptide called “Releasing Protein (CCK-RP)” is released. The cholecystokinin releasing protein then stimulates the release of cholecystokinin in the intestine. Cholecystokinin has been shown to increase satiety. When cholecystokinin is released, it also stimulates the release of an enzyme that inactivates CCK-RP. When CCK-RP is inactivated, CCK levels drop and satiety is reduced. Studies have shown that cholecystokinin is extremely effective in prolonging satiety after eating a meal. Although CCK has been shown to prolong satiety and reduce food intake, the major drawback is that it must be given intravenously. When administered orally, CCK is inactivated by gastrointestinal enzymes. This has severely limited its use as a potential weight loss agent.

多数の栄養剤がコレシストキニンの放出を刺激することができる。研究者達は蛋白質、脂肪（殊に、中鎖脂肪酸）、及びカルシウムがＣＣＫの放出を刺激することを明らかにしてきている。   A number of nutrients can stimulate the release of cholecystokinin. Researchers have shown that proteins, fats (especially medium chain fatty acids), and calcium stimulate the release of CCK.

米国特許第４，４９１，５７８号は、コレシストキニンの放出を刺激することによって飽満を刺激するためにトリプシン阻害剤を経口投与することを開示している。トリプシン阻害剤は、コレシストキニン分泌のための負のフィードバック信号を抑制することによって作用すると仮定された。このようにして、トリプシン阻害剤はコレシストキニンの水準を維持して、それによって飽満を引き延ばした。   US Pat. No. 4,491,578 discloses the oral administration of a trypsin inhibitor to stimulate satiety by stimulating the release of cholecystokinin. It was hypothesized that trypsin inhibitors act by suppressing negative feedback signals for cholecystokinin secretion. In this way, trypsin inhibitors maintained cholecystokinin levels, thereby prolonging satiety.

多くの研究が、ジャガイモから抽出されたプロテイナーゼ阻害剤がコレシストキニンの放出を刺激することを明らかにしている。
経口摂取でき、食事の開始前にコレシストキニンの水準を刺激し、そして食事の消費の後の長時間にわたりコレシストキニンの水準及び飽満を維持する栄養干渉組成物が当業において明確に必要とされている。この発明の重要な要素は、食事の前の特定の間隔で摂取される製品の設計である。従って、飽満の水準は食事の前に既に増大され、食事中に消費される食物の量を減少させる。 Many studies have shown that proteinase inhibitors extracted from potato stimulate the release of cholecystokinin.
There is a clear need in the art for nutritional interference compositions that can be taken orally, stimulate cholecystokinin levels before the start of the meal, and maintain cholecystokinin levels and satiety for long periods after consumption of the meal It is said that. An important element of this invention is the design of the product that is taken at specific intervals before the meal. Thus, the level of satiety is already increased before a meal, reducing the amount of food consumed during the meal.

発明の概要Summary of the Invention

本発明は、食事の摂取後に飽満を引き延ばすための乾燥粉末形態の栄養組成物を提供する。
その乾燥栄養組成物は、１０％〜８０％の範囲の蛋白質を含む。その蛋白質は、大豆、ホエー、カゼイン、または必須アミノ酸含有特定アミノ酸混合物、あるいはアミノ酸フェニルアラニンの特定アミノ酸混合物であり得る。 The present invention provides a nutritional composition in dry powder form for prolonging satiety after eating a meal.
The dry nutritional composition contains protein in the range of 10% to 80%. The protein can be soybean, whey, casein, or a specific amino acid mixture containing essential amino acids, or a specific amino acid mixture of the amino acid phenylalanine.

この乾燥栄養組成物は、２％〜６％の範囲のミネラルカルシウムも含む。そのカルシウムは、塩化カルシウム、炭酸カルシウム、乳酸カルシウム等を包含する塩の形であり得る。   This dry nutritional composition also contains mineral calcium in the range of 2% to 6%. The calcium can be in the form of a salt including calcium chloride, calcium carbonate, calcium lactate and the like.

この乾燥栄養組成物は、１０％〜４０％の範囲の中鎖及び／または長鎖脂肪酸（Ｃ12−Ｃ22）も含む。
この乾燥栄養組成物は、ジャガイモから抽出されたプロテイナーゼ阻害剤の源をも含み、そのプロテイナーゼ阻害剤は０．０２％〜５％の範囲で存在する。 The dry nutritional composition, 10% to 40% of the chain and / or long chain fatty acid in the range (C 12 -C 22) including.
The dry nutritional composition also includes a source of proteinase inhibitor extracted from potato, the proteinase inhibitor being present in the range of 0.02% to 5%.

好適な実施態様の詳細な記述Detailed Description of the Preferred Embodiment

飽満を引き延ばすための栄養干渉用栄養組成物は、栄養剤を含み、それら栄養剤は蛋白質、中及び／または長鎖脂肪酸、カルシウム、プロテイナーゼ阻害剤を含有するジャガイモのエキス、そして好ましい形態では、香味剤及び着色剤を含む。プロテイナーゼ阻害剤は、ジャガイモ中及びジャガイモエキス中に存在する熱安定性蛋白質であり、ほぼ２１，０００の分子量を有する。それはトリプシン及びキモトリプシン両阻害剤であり、その重要な機能はコレシストキニンの放出を刺激することである。所望の活性を有するプロテイナーゼ阻害剤は、ジャガイモ中に、そしてより濃厚な形で市販ジャガイモエキス、または粗いジャガイモ粉及びジャガイモ繊維のようなジャガイモ画分中に、存在する。特に、ノンパリエル（Ｎｏｎｐａｒｉｅｌ）社から入手できる粗ジャガイモ粉は１グラム当たり約０．４９ｍｇのプロテイナーゼ阻害剤対を含み、またオランダのアヴェベ（Ａｖｅｂｅ）社から入手できるＰａｓｅｌｌｉ ＰＰＣジャガイモ粉は、１グラム当たりやく１．３５ｍｇのジャガイモプロテアーゼ阻害剤対を含む。本発明の所望の活性を持つ比較的純粋なプロテイナーゼ阻害剤の抽出方法は、Ｂｒｙａｎｔ，Ｊ．，Ｇｒｅｅｎ，Ｔ．Ｒ．Ｇｕｒｕｓａｄｄａｌａｈ，Ｔ．，及びＲｙａｎ，Ｃ．Ａ．の（１９７６），Ｂｉｏｃｈｅｍ．１５，３４１８に記載されている。 The nutritional composition for interfering nutrition to prolong satiety comprises nutrients, which are protein, medium and / or long chain fatty acids, calcium, potato extract containing proteinase inhibitors, and in preferred forms, Contains flavoring and coloring agents. Proteinase inhibitors are thermostable proteins present in potatoes and potato extracts and have a molecular weight of approximately 21,000. It is an inhibitor of both trypsin and chymotrypsin, and its important function is to stimulate the release of cholecystokinin. Proteinase inhibitors with the desired activity are present in potatoes and in more concentrated forms of commercial potato extracts or potato fractions such as coarse potato flour and potato fiber. In particular, the crude potato flour available from Nonpariel contains about 0.49 mg proteinase inhibitor pairs per gram, and the Paselli PPC potato flour available from Avebe, the Netherlands is fast per gram. Contains 1.35 mg of potato protease inhibitor pair. Methods for extracting relatively pure proteinase inhibitors with the desired activity of the present invention are described by Bryant, J. et al. Green, T .; R. Gurusaddalah, T .; , And Ryan, C .; A. (1976), Biochem . 15, 3418.

実験１
この研究は、平均ＢＭＩ＝３１．２ｋｇ／ｍ2（範囲２７．０〜３５．８）及び平均年齢＝３０．９歳（範囲２２〜４５歳）の２１人の被験者で行われた。二つの群からなるクロスオーバー計画であった。第１の相では、被験者は、その等カロリー組成が栄養ドリンク組成物に等しいプラシーボ、または栄養ドリンク組成物を与えられた。両方の処理剤は食事の前１５分に８オンスの水で服用された。食事は、４６０カロリーであった。被験者は食事を１５分内に食い尽くすことが要求された。食事を摂った後に被験者は、３．５時間にわたって１５分毎に６つの視覚アナログスケールで、空腹及び飽満感を評定するように依頼された。 Experiment 1
This study was conducted with 21 subjects with an average BMI = 31.2 kg / m 2 (range 27.0-35.8) and an average age = 30.9 years (range 22-45 years). It was a crossover plan consisting of two groups. In the first phase, subjects were given a placebo, or nutritional drink composition, whose isocaloric composition was equal to the nutritional drink composition. Both treatments were taken with 8 ounces of water 15 minutes before meals. The meal was 460 calories. The subject was required to eat the meal within 15 minutes. After having eaten, subjects were asked to rate hunger and satiety on a 6 visual analog scale every 15 minutes for 3.5 hours.

その栄養ドリンク組成物は、下に示されている。   The nutritional drink composition is shown below.

Figure 2005336208
Figure 2005336208

栄養ドリンク組成物の摂取後の空腹評定は、食後測定期間全体にわたって著しく低減し、食後３時間までに３０％の低減に達した（ｐ＝０．０３３）。この知見と一致して、飽満評定は食後３時間から顕著に大きくなった（３７％増大、ｐ＝０．０４３）。空腹関連事項、または渇きの主観的評定における差異は、両条件の間で観察されなかった。   The hunger rating after ingestion of the energy drink composition was significantly reduced throughout the postprandial measurement period, reaching a 30% reduction by 3 hours postprandial (p = 0.033). Consistent with this finding, satiety ratings increased significantly from 3 hours after meal (37% increase, p = 0.043). No differences in hunger related or thirst subjective ratings were observed between the two conditions.

従って、本発明の一利点は、本発明が食事の終了後飽満を引伸ばしそして空腹を低減するための栄養干渉組成物を提供することである。
実験２
この研究は、平均ＢＭＩ＝３１．２ｋｇ／ｍ2（範囲２７．０〜３５．８）及び平均年齢＝３０．９歳（範囲２２〜４５歳）の２１人の被験者で行われた。規定食餌期中に被験者は、昼食及び夕食の前１５分に毎日２回実験１の栄養ドリンク組成物８オンス（８０ｋｃａｌ）を飲んだ。飽満に対するその栄養ドリンク組成物の効果を規定食餌期の前及び４週間の規定食餌期に研究室で測定した。間隔を置いた日に、３５０カロリーの食事の前１５分に、被験者は本栄養ドリンク組成物飲料、またはプラシーボ飲料（容積及びエネルギーについて釣合わせた）を摂取した。被験者は、３．５時間にわたり１５分毎に視覚アナログスケールで飽満及び空腹を評定した。 Thus, one advantage of the present invention is that it provides a nutritional interference composition for increasing satiety and reducing hunger after the end of a meal.
Experiment 2
This study was conducted with 21 subjects with an average BMI = 31.2 kg / m 2 (range 27.0-35.8) and an average age = 30.9 years (range 22-45 years). During the regular diet, subjects drank 8 oz (80 kcal) of the nutritional drink composition of Experiment 1 twice daily for 15 minutes before lunch and dinner. The effect of the nutritional drink composition on satiety was measured in the laboratory before the regular diet and at the regular diet of 4 weeks. On an interval day, subjects took the nutritional drink composition beverage, or placebo beverage (balanced for volume and energy), 15 minutes before the 350 calorie meal. Subjects rated satiety and hunger on a visual analog scale every 15 minutes for 3.5 hours.

研究の結果は、規定食餌での４週間後、昼食後の満腹評価は、プラシーボ飲料よりも本栄養ドリンク組成物の摂取後の方が高かった（全ての時間間隔についての平均±ＳＤ＝７１．０±１７．３に対し６５．５±１６．７、ｐ＜０．０５）。空腹評価はプラシーボ飲料よりも本プロテアーゼ阻害剤の後が３２％低かった（１０．５±１２．０に対して１５．４±１３．３、ｐ＜０．０１）。本栄養ドリンク組成物に対しての副作用はなく、被験者は本栄養ドリンク組成物が彼等の食物取込みを低減する助けとなったと報告した。体重減少は顕著であった（４週間で２．０±１．１ｋｇ、ｐ＜０．０５）。   The results of the study showed that after 4 weeks on the diet, the satiety assessment after lunch was higher after ingestion of the nutritional drink composition than the placebo beverage (mean ± SD for all time intervals = 71. 0 ± 17.3 versus 65.5 ± 16.7, p <0.05). The hungry rating was 32% lower after the protease inhibitor than the placebo beverage (15.4 ± 13.3 vs 15.4 ± 13.3, p <0.01). There were no side effects on the nutritional drink composition, and subjects reported that the nutritional drink composition helped reduce their food intake. Weight loss was significant (2.0 ± 1.1 kg, p <0.05 over 4 weeks).

従って、本発明の一利点は、３０日の期間にわたり継続的な効果を与え、そして飽満を引延ばすことによって、顕著な体重減少をもたらすことである。
プロテアーゼ阻害剤の源は本発明の飽満引延ばし製品のための個々の応用に応じて変わり得る。例えば、粗ジャガイモ粉は著量のプロテアーゼ阻害剤を含むが、それは水に分散させるのが困難である。当業者は、上記に示された本発明の教示に従って、プロテアーゼ阻害剤の適切な源、ならびに食感、味等の特性を改善するために組成物に添加することができるその他の成分の決定を容易に行うことができる。上記の説明は多くの特定事項を含むが、これらは本発明の範囲を限定するものとして解釈されるべきでなく、本発明の現在の好ましい具体例をのいくつかの例示を与えるに過ぎない。 Thus, one advantage of the present invention is that it provides a significant effect on weight loss by providing a continuous effect over a period of 30 days and prolonging satiety.
The source of the protease inhibitor may vary depending on the particular application for the satiety extended product of the present invention. For example, crude potato flour contains significant amounts of protease inhibitors, which are difficult to disperse in water. Those skilled in the art will be able to determine the appropriate source of protease inhibitors as well as other ingredients that can be added to the composition to improve texture, taste, and other properties in accordance with the teachings of the invention set forth above. It can be done easily. While the above description includes a number of specific details, these should not be construed as limiting the scope of the invention, but merely give some illustrations of the presently preferred embodiments of the invention.

は、食事後の３．５時間にわたる１５分間隔での飽満感に関しての被験者の応答のグラフ表示であり、プラシーボを投与された被験者、及び本発明による栄養サプリメントを投与された被験者の両方を示している。Is a graphical representation of a subject's response regarding satiety at 15 minute intervals over 3.5 hours after a meal, both for subjects who received a placebo and for subjects who received a nutritional supplement according to the present invention. Show. は、食事後の３．５時間にわたる１５分間隔での空腹感に関しての被験者の応答のグラフ表示であり、プラシーボを投与された被験者、及び本発明による栄養サプリメントを投与された被験者の両方を示している。Is a graphical representation of a subject's response with respect to hunger at 15 minute intervals over a 3.5 hour period after a meal, showing both a subject receiving a placebo and a subject receiving a nutritional supplement according to the present invention. ing.

Claims (5)

水と混合して食前に摂取し、飽満を延長しそれによって食欲を減少させる乾燥粉末形態の栄養組成物であって：
（ａ）その乾燥組成物の約１０〜約８０重量％をなす蛋白質；
（ｂ）その乾燥組成物の約１０〜約４０重量％をなす１種またはそれ以上の脂肪酸；
（ｃ）その乾燥組成物の約２〜約５重量％をなすカルシウム塩；及び
（ｄ）その乾燥組成物の約０．０２〜約５重量％をなす、プロテイナーゼ阻害剤源を供給するジャガイモのエキス；
を含む上記栄養組成物。 A nutritional composition in the form of a dry powder that is mixed with water and taken before meals to prolong satiety and thereby reduce appetite:
(A) a protein comprising about 10 to about 80% by weight of the dry composition;
(B) one or more fatty acids comprising about 10 to about 40% by weight of the dry composition;
(C) a calcium salt comprising from about 2 to about 5% by weight of the dry composition; and (d) from about 0.02 to about 5% by weight of the dry composition of a potato supplying a proteinase inhibitor source. extract;
A nutritional composition as described above. 脂肪酸がオレイン酸を含む請求項１に記載の栄養組成物。   The nutritional composition according to claim 1, wherein the fatty acid comprises oleic acid. リンゴ、バナナ、サクランボ、シナモン、クランベリー、ブドウ、ハニーデュウ、ハチミツ、キウイ、レモン、ライム、オレンジ、モモ、ペパーミント、パイナップル、ラズベリー、タンジェリン、スイカ、及びワイルドチェリーの天然エキス及び人造エキス成分を包含する群より選択された水溶性香味料をさらに含む請求項１に記載の栄養組成物。   A group that includes natural and artificial extracts of apples, bananas, cherries, cinnamon, cranberries, grapes, honeydew, honey, kiwi, lemon, lime, orange, peach, peppermint, pineapple, raspberry, tangerine, watermelon, and wild cherry. The nutritional composition according to claim 1, further comprising a more selected water-soluble flavorant. 青、緑、オレンジ、赤、青紫、及び黄の水溶性の天然または人工染料を包含する群より選択された着色料をさらに含む請求項１に記載の栄養組成物。   The nutritional composition of claim 1 further comprising a colorant selected from the group comprising water-soluble natural or artificial dyes of blue, green, orange, red, bluish purple, and yellow. 鉄酸化物色素、青、桃、赤及び青紫のウルトラマリン顔料を包含する群より選択された着色料をさらに含む請求項１に記載の栄養組成物。   The nutritional composition of claim 1 further comprising a colorant selected from the group comprising iron oxide pigments, blue, peach, red and blue-violet ultramarine pigments.
JP2005235268A 1999-07-27 2005-08-15 Composition for extending post meal satiety Pending JP2005336208A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14589299P 1999-07-27 1999-07-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001521331A Division JP2003508490A (en) 1999-07-27 2000-07-25 Composition for extending postprandial satiety

Publications (1)

Publication Number Publication Date
JP2005336208A true JP2005336208A (en) 2005-12-08

Family

ID=22515008

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001521331A Pending JP2003508490A (en) 1999-07-27 2000-07-25 Composition for extending postprandial satiety
JP2005235268A Pending JP2005336208A (en) 1999-07-27 2005-08-15 Composition for extending post meal satiety

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001521331A Pending JP2003508490A (en) 1999-07-27 2000-07-25 Composition for extending postprandial satiety

Country Status (8)

Country Link
EP (1) EP1115409A4 (en)
JP (2) JP2003508490A (en)
KR (1) KR20010075394A (en)
AU (1) AU779377C (en)
BR (1) BR0006959A (en)
CA (1) CA2348067A1 (en)
MX (1) MXPA01003054A (en)
WO (1) WO2001017541A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010172304A (en) * 2009-01-30 2010-08-12 Toyo Shinyaku Co Ltd Method for improving taste of potato extract-containing food
JP2010273552A (en) * 2009-05-26 2010-12-09 Toyo Shinyaku Co Ltd Diet composition
JP5721232B2 (en) * 2009-12-04 2015-05-20 株式会社東洋新薬 Glucagon-like peptide-1 secretion promoter

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686456B2 (en) 2001-07-06 2004-02-03 Kemin Foods, L.C. Method for the elimination of Kunitz and Bowman-Birk trypsin inhibitors and carboxypeptidase inhibitor from potato proteins
JP2005015358A (en) * 2003-06-25 2005-01-20 Pharma Design Inc Medicinal composition used for treating eating disorder
WO2006110731A2 (en) * 2005-04-11 2006-10-19 University Of Tennessee Research Foundation Stable dairy components effective for fat loss
JP2010094085A (en) * 2008-10-17 2010-04-30 Pola Chem Ind Inc Food composition for dieting use
DK2227966T3 (en) * 2009-02-25 2016-09-12 Coöperatie Avebe U A Spice
CN107334875A (en) * 2017-08-30 2017-11-10 南宁学院 A kind of medicinal liquor for treating diarrhoea and preparation method thereof
CN111493254A (en) * 2020-04-10 2020-08-07 苏州绿叶日用品有限公司 A solid beverage containing rhizoma Solani Tuber osi extract and its preparation method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833128A (en) * 1984-12-28 1989-05-23 Neil Solomon Dietary supplement

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491578A (en) * 1982-06-14 1985-01-01 Peikin Steven R Method of stimulating satiety in mammals
JPH0699321B2 (en) * 1990-01-22 1994-12-07 不二製油株式会社 Appetite suppressant and food containing the same
US5468727A (en) * 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
NZ260933A (en) * 1993-07-16 1996-07-26 Hercules Inc Cation-complexed polysaccharides; use in foods and pharmaceuticals
US5340603A (en) * 1993-08-30 1994-08-23 Abbott Laboratories Nutritional product for human infants having chronic lung disease
KR100406912B1 (en) * 1994-08-05 2004-02-18 위스콘신 얼럼나이 리서어치 화운데이션 CCK Antibodies Used to Improve Feed Efficiency
US5595772A (en) * 1995-06-07 1997-01-21 Massachusetts Institute Of Technology Composition and methods for losing weight
ATE362715T1 (en) * 1997-06-23 2007-06-15 Nestle Sa COMPOSITION FOR THE NUTRITION OF DIABETIC PEOPLE
US6475539B1 (en) * 1998-05-07 2002-11-05 Abbott Laboratories Nutritionally complete low pH enteral formula
US6051236A (en) * 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
US6025363A (en) * 1998-11-17 2000-02-15 Giles, Jr.; James A. Composition for suppressing appetite

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833128A (en) * 1984-12-28 1989-05-23 Neil Solomon Dietary supplement

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010172304A (en) * 2009-01-30 2010-08-12 Toyo Shinyaku Co Ltd Method for improving taste of potato extract-containing food
JP2010273552A (en) * 2009-05-26 2010-12-09 Toyo Shinyaku Co Ltd Diet composition
JP5721232B2 (en) * 2009-12-04 2015-05-20 株式会社東洋新薬 Glucagon-like peptide-1 secretion promoter

Also Published As

Publication number Publication date
AU6370400A (en) 2001-04-10
BR0006959A (en) 2001-06-26
AU779377C (en) 2005-06-30
JP2003508490A (en) 2003-03-04
EP1115409A1 (en) 2001-07-18
WO2001017541A1 (en) 2001-03-15
EP1115409A4 (en) 2005-04-13
AU779377B2 (en) 2005-01-20
CA2348067A1 (en) 2001-03-15
KR20010075394A (en) 2001-08-09
MXPA01003054A (en) 2003-07-14

Similar Documents

Publication Publication Date Title
JP2005336208A (en) Composition for extending post meal satiety
US6838431B2 (en) Nutritional intervention composition containing a source of proteinase inhibitor extending post meal satiety
TW410160B (en) Adolescent dietary composition
US6383482B1 (en) Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US8388949B2 (en) Compositions comprising pantothenic acid and their use for stimulating appetite
CN101212961A (en) HMB compositions and uses thereof
TW201304768A (en) Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
JP2003523368A (en) Nutrition intervention compositions to increase and maintain satiety
GB2323531A (en) Serenoa Repens
JP2009173634A (en) LIPID ABSORPTION INHIBITOR CONTAINING POLY-gamma-GLUTAMIC ACID
US6265391B1 (en) Method for preventing peripheral nerve damage
US20030004211A1 (en) Carbohydrate modifying agent and drinks containing the modifying agent
AU2002305703A1 (en) Carbohydrate modifying agent and drinks containing the modifying agent
WO2005122798A1 (en) Functional beverage composition for improving ability of learning, concentration and memory
CN102711803A (en) GLP-2 for use in intestine and muscle recovery
US20040077530A1 (en) Composition for reducing caloric intake
US20030017219A1 (en) Carbohydrate modifying agent and drinks containing the modifying agent
JP4445145B2 (en) Oral composition
Giampapa Every man takes the limits of his own field of vision for the limits of the world.
CN115606806A (en) Dietary composition useful for preventing and controlling obesity
JP2003516946A (en) Compositions for improving the proliferative response during gastrointestinal adaptation and use in short bowel syndrome
KR20070001631A (en) Anti-obesity composition including extracts of acanthopanax senticosus
WO2002096451A1 (en) Carbohydrate modifying agent and drinks containing the modifying agent
TW201021820A (en) Formulations and methods for increasing metabolic rate, burning calories, thermogenesis and total weight control
JP2011097917A (en) Composition for dieting

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101005

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101008

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110317